Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod + Atezolizumab +/- Radiation in Advanced NSCLC
NCT03438318Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of vidutolimod in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events and Dose-Limiting Toxicity. Started Mar 2018; status: completed.
02
Drugs
vidutolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03438318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03438318.